British Peripheral Nerve Society

This meeting is open to BPNS members and other professionals working in relevant areas, but not to patients or members of the general public without advance permission.
BPNS members wishing to register for the meeting may benefit from a reduced registration fee if they log in to the website first.

BPNS Spring Meeting 2021

Start Date

End Date

Friday 19 Mar 2021 09:30 AM

Friday 19 Mar 2021 13:00 PM

Location

Zoom meeting hosted by the Institute of Neurological Sciences, Glasgow

Details

There will be two invited lectures for this online only event:

Dr Ann Louise Oaklander - Small Fibre Neuropathy

Prof Hugh Willison - Guillain Barre Syndrome: An experience

Submission of cases is now invited through the website as usual.

At this and subsequent meetings the society will offer a prize of £500 for the best presentation given by a trainee, to be judged by the current and past presidents of the society and the case library editor.

Submit an abstract for consideration

Programme

Date	Time	Type		Presenter
Fri 19 Mar 2021	09:25	Registration
Fri 19 Mar 2021	09:30	Lecture	GBS – an evolution	Professor Hugh Willison Professor of Neurology University of Glasgow Honorary NHS Consultant Neurologist, Queen Elizabeth University Hospital, Glasgow
Fri 19 Mar 2021	10:10	Abstract	Occam's Razor - The Achilles Heel of the Neurology Clinic?	Dr Chris Graham
Fri 19 Mar 2021	10:25	Abstract	A Sting in the Tale	Dr Rebecca Cooper
Fri 19 Mar 2021	10:40	Refreshment	Refreshment Break
Fri 19 Mar 2021	11:00	Abstract	Paranodal Antibodies: you wait months for one and then...the Glasgow experience	Dr Ilesha Ewart
Fri 19 Mar 2021	11:15	Abstract	Beware the square peg – when an acronym doesn't fit.	Dr Alex Grundmann
Fri 19 Mar 2021	11:30	Abstract	Ascending numbness with pupillary involvement	Dr Anna Nagy
Fri 19 Mar 2021	11:45	Abstract	Baseline variation in commonly used inflammatory neuropathy clinical outcome measures	Dr Ryan Keh
Fri 19 Mar 2021	12:00	Lecture	Small fibres, big reach	Dr Anne Louise Oaklander, Director, MGH Nerve Unit & Neuropathology Skin Biopsy Service, Associate Professor of Neurology, Harvard Medical School, Assistant in Pathology, Massachusetts General Hosp.
Fri 19 Mar 2021	12:40	Close

Lost driving licence

Jiten Mistry misplaced his driving licence at the Belfast meeting. If anyone picked it up, please could they contact him at jitenmistry@nhs.net.

Queen Square Annual Update in Neuromuscular Disorders

This course will be held from Wednesday 13th May to Friday 15th May in the Clinical Neuroscience Lecture Theatre, Lower ground, 33 Queen Square, London WC1N 3BG

DETAILS/REGISTRATION

Brain Fellowships

Applications are invited for 1 year fellowships funded by the Guarantors of Brain. These fellowships provide bridging salary support to early career clinicians based in the UK prior to obtaining a research fellowship. Further details can be found HERE

New NHSE commissioning policies for rituximab and IVIg

We are pleased to announce that, largely due to the efforts of our president Prof Lunn, rituximab is now approved for treatment of IgM paraproteinaemic demyelinating peripheral neuropathy (anti-MAG phenotype, with or without anti-MAG antibodies): 1910-rituximab-for-treatment-of-PDPN-policy-v2.pdf (england.nhs.uk). Whilst we have hitherto been able to treat some patients with rituximab by sending them to a haematologist, this was not possible if the bone marrow showed insufficient evidence of underlying lymphoplasmacytic lymphoma. These patients can now be treated, regardless of bone marrow result, either by you or by your friendly haematologist, under the new commissioning guidance.
Also thanks to Prof Lunn (alongside non-neurology colleagues), the updated IVIg commissioning policy is now available: Commissioning-Criteria-Policy-for-the-use-of-Ig-Version-Finala.pdf (mdsas.com). Newly commissioned diagnoses of relevance to peripheral nerve now include acute autoimmune autonomic ganglionopathy, and neuromyotonia.
Finally, with thanks largely to the efforts of Dr Rinaldi in Oxford, rituximab can now be used for the treatment of autoimmune nodopathies (with nodal/paranodal antibodies): NHS England » Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children.

More news »

Meetings

Lost driving licence

Queen Square Annual Update in Neuromuscular Disorders

Brain Fellowships

New NHSE commissioning policies for rituximab and IVIg